ReviewCurrent oncology reports2026
Unveiling the Intricate Dance: Signaling Pathways in Liver Cancer Metabolism and Immunity.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewHepatocellular carcinoma is a type of cancer with high rates of occurrence and death worldwide. Recently, the marked increase in liver cancer risk among patients with metabolic-associated steatotic liver disease has drawn considerable attention to the metabolic-immune evolutionary mechanisms underlying this condition. In this article, we systematically review the main metabolic-immune signaling pathways linked to the advancement of hepatic steatosis, inflammation, and carcinogenesis. This review examines their roles and potential therapeutic significance within the tumor microenvironment, with the objective of furnishing a theoretical foundation and identifying novel therapeutic targets for the precise treatment. RECENT
findingsThe carcinogenic process entails complex and dynamic interactions between energy metabolism and immune cells. The latest studies focusing on metabolic-immune interactions bring attention to significant signaling routes such as PI3K/AKT/mTOR and AMPK. These pathways regulate energy metabolism reprogramming in the HCC microenvironment and facilitate tumor immune evasion, impacting tumor growth and metastasis. Hepatocellular carcinoma significantly contributes to global cancer mortality, with existing treatments showing limited effectiveness, thus heavily burdening public health systems.The carcinogenic process of hepatocellular carcinoma is characterized by a multitude of pathogenic mechanisms, notably the intricate interplay between energy metabolism and immune functions, which involves numerous signaling pathways. Thoroughly analyzing the regulatory mechanisms of these signaling routes could lay a theoretical groundwork for finding new therapeutic targets and bettering the prognosis for hepatocellular carcinoma patients.
Indexed as
Identifiers
42060013What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.